Yazar "Yildiz, Ferah" seçeneğine göre listele
Listeleniyor 1 - 3 / 3
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Boost dose back again in elderly(AMER SOC CLINICAL ONCOLOGY, 2007) Gultekin, Melis; Selek, Ugur; Ozyigit, Gokhan; Cengiz, Mustafa; Yavas, Ozlem; Yildiz, Ferah[Abstract not Available]Öğe Radiotherapy in the management of Kaposi's sarcoma: Comparison of 8 Gy versus 6 Gy(NATL MED ASSOC, 2006) Yildiz, Ferah; Genc, Mine; Akyurek, Serap; Cengiz, Mustafa; Ozyar, Enis; Selek, Ugur; Atahan, I. LaleObjective: To evaluate prospectively the efficacy of a single fraction of high-dose radiotherapy in patients with Kaposi's sarcoma. Patients: Between 1994 and 2004, 47 patients with Kaposi's sarcoma were treated at Hacettepe University, Department of Radiation Oncology. Thirteen (28%) patients received chemotherapy before radiotherapy and were referred due to recurrent or progressive disease or intolerance to chemotherapy. All lesions were treated locally with a 2-3-cm safety margin with 4-6-MeV electron beams. Radiotherapy consisted of a single fraction of 8 Gy in the first four years and 6 Gy thereafter. Results: The male:female ratio was 4:1. The median age was 61 years (range 18-87). Eight out of 47 patients (17%) had an underlying immunocompromised state, and one had a previous diagnosis of Hodgkin's disease. Of 203 fields treated, 51 and 152 fields were treated with 8 Gy and 6 Gy, respectively. Overall response rates (RR) at 12 months for 8- and 6 Gy were 93% and 86%, which were not statistically different. However, the difference between complete RRs at 12 months (93% and 60% for 8 Gy and 6 Gy respectively) was significant (p < 0.0001). Progression-free survival and reirradiation rates were not significantly different. Side effects were tolerable in all but three patients with grade 2-3 fibrosis and edema. Conclusion: Radiotherapy is an effective mode of treatment for Koposi's sarcoma, and a single dose of 8 Gy is more effective in terms of complete RR compared to 6 Gy, though overall response and progression-free survival rates were similar.Öğe Salvage Stereotactic Body Radiosurgery in the Management of Recurrent Gynecological Cancer(AKAD DOKTORLAR YAYINEVI, 2013) Yazici, Gozde; Cengiz, Mustafa; Ozyigit, Gokhan; Yavas, Guler; Ayhan, Ali; Gurkaynak, Murat; Yildiz, FerahLocal tumor persistence in the pelvis is the major cause of death in patients with recurrent gynecological cancer. Pelvic exenteration has been the only treatment option providing a chance for cure in selected patients. The aim of this study is to analyze the efficacy of stereotactic body radiosurgery (SBRS) in patients with recurrent gynecological cancer. Sixteen patients treated with SBRS were analyzed retrospectively. The majority of the patients had cervical cancer. Eleven patients had a history of prior radiotherapy either as postoperative adjuvant external beam radiotherapy (EBRT) with a median dose of 50.4 Gy (range 45-60 Gy) or definitive chemoradiotherapy as EBRT and high dose rate brachytherapy with a dose of 85-90 Gy low dose rate equivalent to point A. The prescribed dose of SBRS was 15-40 Gy (mean 26.6 Gy) in 3-5 fractions. Five patients with no prior radiotherapy received additional EBRT before SBRS. The median follow-up in all patients is 12 months (range 3-36 months). Six patients (37.5%) showed complete radiological and functional response to salvage SBRS. Six patients (37.5%) showed partial response and 2 (12.5%) showed stable disease. One and 2 year overall survival rates are 60.3% and 40.2% respectively. Progression free survival is 59%. All patients with complete response after SBRS are alive with no evidence of disease with a median follow up time of 20 months. SBRS is a promising treatment modality with high local Control and reasonable complication rates in selected patients with recurrent gynecological cancer.